Alishba Fatima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alishba Fatima has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Hasnain Azeem
Dow University of Health Sciences, Karachi, Pakistan
5 shared publications - Rida Shakeel
Department of Surgery, Dow Medical College, Karachi, Pakistan
4 shared publications - Danish Hassan
Dow Medical College, DUHS, Karachi, Pakistan
3 shared publications - Emad Uddin Sajid
Department of Medicine Dow University of Health Sciences Karachi Pakistan
3 shared publications - Syed Rayyan Ahmed
Department of Medicine Dow University of Health Sciences Karachi Pakistan
3 shared publications - Kashish Zehra Manjee
Department of Medicine Dow University of Health Sciences Karachi Pakistan
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 53 (1) , 89
An unusual presentation of Juvenile-onset systemic lupus erythematosus: Budd–Chiari syndrome with secondary antiphospholipid syndrome and lupus nephritis: a case report
Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease affecting young women. Budd–Chiari syndrome (BCS), caused by hepatic venous outflow obstruction, is a rare manifestation often associated with secondary antiphospholipid syndrome (APS). Case summary: A 17-year-old girl presented with progressive abdominal distension, pedal edema, fever, weight loss, arthralgia, oral ulcers, alopecia, and amenorrhea. Initially managed as chronic liver disease after recurrent presumed spontaneous bacterial peritonitis, imaging revealed chronic BCS. Further evaluation demonstrated positive antinuclear and anti-double-stranded DNA antibodies, hypocomplementemia, proteinuria, and Class IV lupus nephritis. Persistent antiphospholipid antibody positivity confirmed secondary APS. Treatment with corticosteroids, mycophenolate mofetil, hydroxychloroquine, and planned indefinite anticoagulation resulted in marked clinical improvement. Conclusion: SLE with secondary APS should be considered in young women presenting with unexplained BCS to enable early diagnosis, prompt immunosuppressive therapy, and prevention of irreversible organ damage.
- 3 November 2026
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 53 (1) , 89
Open AccessAn unusual presentation of Juvenile-onset systemic lupus erythematosus: Budd–Chiari syndrome with secondary antiphospholipid syndrome and lupus nephritis: a case report
Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease affecting young women. Budd–Chiari syndrome (BCS), caused by hepatic venous outflow obstruction, is a rare manifestation often associated with secondary antiphospholipid syndrome (APS). Case summary: A 17-year-old girl presented with progressive abdominal distension, pedal edema, fever, weight loss, arthralgia, oral ulcers, alopecia, and amenorrhea. Initially managed as chronic liver disease after recurrent presumed spontaneous bacterial peritonitis, imaging revealed chronic BCS. Further evaluation demonstrated positive antinuclear and anti-double-stranded DNA antibodies, hypocomplementemia, proteinuria, and Class IV lupus nephritis. Persistent antiphospholipid antibody positivity confirmed secondary APS. Treatment with corticosteroids, mycophenolate mofetil, hydroxychloroquine, and planned indefinite anticoagulation resulted in marked clinical improvement. Conclusion: SLE with secondary APS should be considered in young women presenting with unexplained BCS to enable early diagnosis, prompt immunosuppressive therapy, and prevention of irreversible organ damage.
- 9 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Clinical Outcomes of Conduction System versus Right Ventricular Pacing after TAVR: A Systematic Review and Meta‐Analysis
Background: Permanent pacemaker implantation is required in up to 25% of patients after transcatheter aortic valve replacement (TAVR). Conventional right ventricular pacing (RVP) may promote dyssynchrony, whereas conduction system pacing (CSP) preserves physiological activation. Research Question: Does CSP improve clinical, echocardiographic, electrical, and procedural outcomes compared with RVP in patients requiring pacing after TAVR? Methods: We conducted a PROSPERO‐registered systematic review and meta‐analysis following PRISMA 2020. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through June 2026 for randomized and comparative observational studies of CSP versus RVP after TAVR. Random‐effects models generated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Prediction intervals, cumulative meta‐analysis, leave‐one‐out analyses, and GRADE assessment were performed. Results: Six studies, one randomized trial and five observational studies, enrolled 675 patients (CSP, n = 344; RVP, n = 331). CSP was associated with fewer heart‐failure hospitalizations (RR 0.49, 95% CI 0.29–0.83; p = 0.017; I 2 = 5%) and shorter paced QRS duration (MD −31.05 ms, 95% CI −34.07 to −28.02; p < 0.001; I 2 = 0%). All‐cause mortality, cardiovascular death, and change in left ventricular ejection fraction did not differ significantly. Implantation success was modestly lower with CSP (RR 0.91; p = 0.014). Conclusion: CSP was associated with fewer heart‐failure hospitalizations and shorter paced QRS duration than RVP after TAVR. Evidence was predominantly observational, and no significant differences were demonstrated in mortality or change in left ventricular ejection fraction. The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.
- 9 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Clinical Outcomes of Conduction System versus Right Ventricular Pacing after TAVR: A Systematic Review and Meta‐Analysis
Background: Permanent pacemaker implantation is required in up to 25% of patients after transcatheter aortic valve replacement (TAVR). Conventional right ventricular pacing (RVP) may promote dyssynchrony, whereas conduction system pacing (CSP) preserves physiological activation. Research Question: Does CSP improve clinical, echocardiographic, electrical, and procedural outcomes compared with RVP in patients requiring pacing after TAVR? Methods: We conducted a PROSPERO‐registered systematic review and meta‐analysis following PRISMA 2020. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through June 2026 for randomized and comparative observational studies of CSP versus RVP after TAVR. Random‐effects models generated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Prediction intervals, cumulative meta‐analysis, leave‐one‐out analyses, and GRADE assessment were performed. Results: Six studies, one randomized trial and five observational studies, enrolled 675 patients (CSP, n = 344; RVP, n = 331). CSP was associated with fewer heart‐failure hospitalizations (RR 0.49, 95% CI 0.29–0.83; p = 0.017; I 2 = 5%) and shorter paced QRS duration (MD −31.05 ms, 95% CI −34.07 to −28.02; p < 0.001; I 2 = 0%). All‐cause mortality, cardiovascular death, and change in left ventricular ejection fraction did not differ significantly. Implantation success was modestly lower with CSP (RR 0.91; p = 0.014). Conclusion: CSP was associated with fewer heart‐failure hospitalizations and shorter paced QRS duration than RVP after TAVR. Evidence was predominantly observational, and no significant differences were demonstrated in mortality or change in left ventricular ejection fraction. The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.
- Open Access
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Open AccessModerate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 8 May 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107222
Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review
- 8 May 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107222
Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review